Women looking to get pregnant: a key for biomarkers discovery
MELISA Institute is continuously recruiting a cohort of couples seeking a pregnancy and collecting samples for a biobank from each day of the fertile cycle and over an ongoing pregnancy. This biorepository is key to investigate potential biomarkers for prenatal medicine.

Towards the first clinical trial of prenatal use of EGCG for Down Syndrome
The use of EGCG from green tea has shown beneficial effects on memory and learning in clinical trials of adults with Down Syndrome. A prenatal supplementation with EGCG during the third-trimester of pregnancy may eventually rescue the nervous system of children carrying Trisomy 21. MELISA Institute and a group of experts on fetal medicine is elaborating the first clinical protocol for prenatal use of EGCG to assess its safety, tolerability, and preliminary efficacy on neurodevelopment after birth.